NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
Press Release / March 27, 2025
Positive Data Showing Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Released at 2025 MDA Conference
We're proud to support Akari Viaja por USA 2025!
Every family should have access to information and community support - so we're thrilled to see The #AkariFoundation bringing such valuable insights and connections!
Learn more: https://ow.ly/v4J050VsZG1
#RareDisease #Duchenne https://x.com/NSPharmaInc/status/1907455721651732548/photo/1
NS Pharma is growing fast! 🚀
We’re expanding our teams as we prepare for an exciting year ahead.
If you're looking to make an impact in the rare disease space and join a passionate, purpose-driven team, visit: https://www.nspharma.com/careers/ 👈
#Hiring #RareDiseases https://x.com/NSPharmaInc/status/1906708608412266662/photo/1
Big news for the #MPS community!
Nippon Shinyaku and REGENXBIO have entered an exclusive partnership to develop and commercialize RGX-121 and RGX-111—two investigational #GeneTherapies for MPS II (Hunter syndrome) and MPS I (Hurler syndrome).
Learn more: https://ow.ly/j5ti50VaSZG https://x.com/NSPharmaInc/status/1905638601100063069/photo/1
Exciting news for the #DuchenneCommunity!💡🎉
We're thrilled to share the latest results from the HOPE-2 clinical trial, showing promising long-term efficacy of #Deramiocel in treating #Duchenne muscular dystrophy cardiomyopathy.
Read the press release: https://ow.ly/bMEa50VpPK7 https://x.com/NSPharmaInc/status/1905286589363691924/photo/1
Say hello to Tara Gorombey, our new Manager of Human Resources! 🎉
With 15+ years of experience, she brings a deep expertise in recruiting for rare diseases and specialized healthcare roles.
Outside of work, Tara enjoys gardening, reading & hiking!
#NewHire #GrowingTeam https://x.com/NSPharmaInc/status/1904896246097002941/photo/1
We're proud to be sponsoring the #PPMDTogether event this weekend in Minneapolis!
After its incredible success last year, it's back March 28-29- and we’re thrilled to be part of it.
If you're attending, be sure to stop by and say hello!
Learn more: https://ow.ly/qQEG50Vnk01 https://x.com/NSPharmaInc/status/1904186953664495835/photo/1
We're en route to New Orleans!
NS Pharma is proud to sponsor another upcoming #Community dinner session hosted by @CureDuchenne, this time in Louisiana!
It's a great opportunity to connect with your community.
Register here: https://ow.ly/Rw0350VkARw
#Duchenne #DMD https://x.com/NSPharmaInc/status/1903099291687620883/photo/1
